Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy

Hepatology

Volumn 34, Issue 4 I, 2001, Pages 785-791

  Yuen, Man Fung ^a   Sablon, Erwin ^b   Hui, Chee Kin ^a   Yuan, He Jun ^a   Decraemer, Hilde ^b   Lai, Ching Lung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b INNOGENETICS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; FAMCICLOVIR; LAMIVUDINE; VIRUS DNA;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VIRUS LOAD;

EID: 0034802516     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.27563     Document Type: Article

References (30)

1. A one-year trial of lamivudine for chronic hepatitis B
2. Lamivudine as initial treatment for chronic hepatitis B in the United States
3. Profound suppression of of hepatitis B virus replication with lamivudine
4. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
5. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation
6. Hepatitis B virus polymerase mutations during famciclovir therapy in patients following liver transplantation
7. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy
8. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
9. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC(3TC) resistance
10. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus
11. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection
12. Liver disease-significant improvement with lamivudine
13. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
14. Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay
15. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy
16. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine
17. Pretherapy alanine transaminase level as a determinant for hepatitis B e-antigen seroconversion during lamivudine patients with chronic hepatitis B
18. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
19. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B
20. Hepatitis B therapy: The plot thickens
21. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B
22. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine
23. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
24. Hepatitis B e-antigen seroconversion in 2 patients with evidence of genotypic resistance following extended lamivudine treatment
25. Debates in hepatitis: How to assess HBV DNA reductions in association with therapy
26. New treatment strategies in hepatitis B and C: Anti-viral therapy for hepatitis B and C in Asians
27. Natural history of chronic hepatitis B in the Chinese: Prognostic significance of HBeAg/anti-HBe positivity
28. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial
29. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation